Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents

Download these expert-selected slides on current best practices and standard treatments for the management of CLL/SLL in the first-line and relapsed settings.
Farrukh T. Awan, MD
Nicole Lamanna, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.37 MB
Released: October 5, 2022

Acknowledgements

Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This CE activity is supported through an educational grant from
AstraZeneca
BeiGene
Lilly

Related Content

Comentario experto de los datos de la Junta Anual de SOHO 2022 sobre inhibidores de la TQB para LLC y LCM de Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Expertengespräch über die Daten der Jahresversammlung der SOHO 2022 zu BTK-Inhibitoren bei CLL und MCL, von Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Commentaires d’experts sur les données de la réunion annuelle de la SOHO 2022 au sujet des inhibiteurs BTK pour le traitement de la LLC et du LCM de Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Comentários de especialistas sobre dados da Reunião Anual da SOHO 2022 sobre os inibidores de BTK para LLC e LCM, do Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings